differentiated thyroid carcinoma(DTC). Malignant neoplasm of thyroid gland
Conditions
Interventions
Intervention 1: Group I: Nano-curcumin tablets, 80 mg orally, twice daily, for 10 days from 3 days before to seven days after radioiodine therapy. Intervention 2: Group II: No nano-curcumin tablets.
Treatment - Drugs
Group I: Nano-curcumin tablets, 80 mg orally, twice daily, for 10 days from 3 days before to seven days after radioiodine therapy
Group II: No nano-curcumin tablets
Sponsors
Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with differentiated thyroid cancer (follicular, papillary or mixed type) don't received destroying dose (ablative dose) of radioiodine up to now; no palpable neck mass; thyroid pathology reported there is no invasion to capsular and lymph areas and blood vessels; body scan with 131-I don’t show any functional tissue in regions other than the thyroid bed; thyroid cancer confirmed by biopsy; all patients have total thyroidectomy; TSH level before administration of radioiodine is higher than 30 IU/ML. exclusion criteria: after treatment with 131 I if there is abnormal tissue absorption of iodine in other areas of the thyroid bed; if patients after taking the first capsule of curcumin had a headache and dizziness; patient will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MN counts in 1000 BN cells. Timepoint: before and 7 days after radioiodine therapy. Method of measurement: blood sampling. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocyte and platelets count. Timepoint: before and 1 week after radioiodine therapy. Method of measurement: blood sample/ CBC. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohsen Bakhshandeh
Shahid Beheshti University of Medical Science
Outcome results
None listed